Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and development costs.
The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in 2023.
To that end, the company bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion in total.
AbbVie expects adjusted annual profit in the range of $11.99 to $12.19 per share, compared with its previous forecast of $12.12 to $12.32 per share.
Analysts on average were expecting full-year profit to be $12.30 per share, according to data compiled by LSEG.
The company also expects first-quarter adjusted profit of $2.34 to $2.38 per share, compared with Wall Street estimates of $2.51 per share.
AbbVie is scheduled to report first-quarter earnings on April 25.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shreya Biswas)
